Modal close

Dear Democracy Now! visitor,

You turn to Democracy Now! for ad-free news you can trust. Maybe you come for our daily headlines. Maybe you come for in-depth stories that expose corporate and government abuses of power. Democracy Now! brings you crucial reporting like our coverage from the front lines of the standoff at Standing Rock or news about the movements fighting for peace, racial and economic justice, immigrant rights and LGBTQ equality. We produce our daily news hour at a fraction of the budget of a commercial news operation—all without ads, government funding or corporate sponsorship. How is this possible? Only with your support. If every visitor to this site in December gave just $10 we could cover our basic operating costs for 2017. Pretty exciting, right? So, if you've been waiting to make your contribution to Democracy Now!, today is your day. It takes just a couple of minutes to make sure that Democracy Now! is there for you and everybody else in 2017.

Non-commercial news needs your support.

We rely on contributions from you, our viewers and listeners to do our work. If you visit us daily or weekly or even just once a month, now is a great time to make your monthly contribution.

Please do your part today.

Topics

Thalidomide

StorySeptember 24, 1997
Watch iconWatch Full Show

The Food and Drug Administration looks set to approve Thalidomide, the drug that caused tens of thousands of horrific birth defects in newly born children all across the world when it was first introduced decades ago. Pregnant women took the drug to ease morning sickness.

The FDA, which banned the drug back in 1960, announced this week that they would approve the drug for use in leprosy patients as long as the Celgene Corporation — the New Jersey drug company which is manufacturing the drug — adheres to strict conditions intended to keep the drug away from women who are or might become pregnant.

Thalidomide victims groups immediately slammed the FDA’s decision, charging — among other things — that the drug would become too widely available through off-label use.

Leprosy affects about 7,000 people in the United States, 250 of whom receive Thalidomide through a Government compassionate use program. But some advocates say that tens of thousands more people with cancers and certain AIDS-related illnesses, including wasting, might also benefit from the drug.

Guests:

  • David Blanco, with LifeLink, a company based in California which now sells Thalidomide over the phone.

Related links:

.
.
.


The original content of this program is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License. Please attribute legal copies of this work to democracynow.org. Some of the work(s) that this program incorporates, however, may be separately licensed. For further information or additional permissions, contact us.

Non-commercial news needs your support

We rely on contributions from our viewers and listeners to do our work.
Please do your part today.

Make a donation